(ATGE) Adtalem Global Education - Ratings and Ratios
Healthcare Education, Degrees, Online Programs, Certificates
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 45.7% |
| Value at Risk 5%th | 58.7% |
| Relative Tail Risk | -21.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -8.79 |
| CAGR/Max DD | 0.86 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.379 |
| Beta | 0.812 |
| Beta Downside | 1.136 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.14% |
| Mean DD | 7.81% |
| Median DD | 4.99% |
Description: ATGE Adtalem Global Education November 07, 2025
Adtalem Global Education Inc. (NYSE: ATGE) operates a portfolio of for-profit institutions that deliver healthcare-focused education across the United States and several Caribbean jurisdictions. Its business is organized into three segments-Chamberlain (nursing and allied health), Walden (online graduate and professional programs), and Medical & Veterinary (medical and veterinary schools). The company offers a range of degree and certificate programs, from bachelor’s to doctoral levels, spanning nursing, health professions, counseling, business, IT, public health, social work, public administration, and criminal justice. Core brands include Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Formerly DeVry Education Group, the firm rebranded to Adtalem in May 2017 and is headquartered in Chicago, Illinois.
Key operational metrics (as of FY 2023) show total enrollment of roughly 65 k students, with online enrollment accounting for about 55 % of the mix-a figure that has risen ~8 % YoY, reflecting broader sector acceleration toward digital delivery. Revenue grew 4.2 % year-over-year to $1.2 bn, while the adjusted EBITDA margin stabilized near 12 %, indicating modest profitability after the 2022 restructuring. A primary economic driver is the sustained U.S. shortage of nurses and allied-health workers, which underpins demand for Chamberlain’s programs; however, enrollment sensitivity to federal student-aid policy changes remains a material risk.
For a deeper, data-driven view of ATGE’s valuation dynamics-including forward-looking cash-flow models and peer-adjusted multiples-explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (252.0m TTM) > 0 and > 6% of Revenue (6% = 110.0m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 2.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.51% (prev -2.11%; Δ 1.59pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 379.1m > Net Income 252.0m (YES >=105%, WARN >=100%) |
| Net Debt (509.8m) to EBITDA (444.4m) ratio: 1.15 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (37.1m) change vs 12m ago -5.25% (target <= -2.0% for YES) |
| Gross Margin 58.51% (prev 56.38%; Δ 2.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 64.49% (prev 57.96%; Δ 6.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.75 (EBITDA TTM 444.4m / Interest Expense TTM 46.7m) >= 6 (WARN >= 3) |
Altman Z'' 6.18
| (A) -0.00 = (Total Current Assets 567.2m - Total Current Liabilities 576.6m) / Total Assets 2.87b |
| (B) 0.99 = Retained Earnings (Balance) 2.84b / Total Assets 2.87b |
| warn (B) unusual magnitude: 0.99 — check mapping/units |
| (C) 0.13 = EBIT TTM 362.0m / Avg Total Assets 2.84b |
| (D) 2.01 = Book Value of Equity 2.84b / Total Liabilities 1.41b |
| Total Rating: 6.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.50
| 1. Piotroski 8.0pt |
| 2. FCF Yield 8.28% |
| 3. FCF Margin 17.63% |
| 4. Debt/Equity 0.53 |
| 5. Debt/Ebitda 1.15 |
| 6. ROIC - WACC (= 6.70)% |
| 7. RoE 17.49% |
| 8. Rev. Trend 92.29% |
| 9. EPS Trend 85.79% |
What is the price of ATGE shares?
Over the past week, the price has changed by +0.76%, over one month by -0.37%, over three months by -30.63% and over the past year by +7.53%.
Is ATGE a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATGE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 166.5 | 76.1% |
| Analysts Target Price | 166.5 | 76.1% |
| ValueRay Target Price | 110.1 | 16.5% |
ATGE Fundamental Data Overview December 03, 2025
P/E Trailing = 14.3471
P/E Forward = 12.285
P/S = 1.8596
P/B = 2.3385
P/EG = 0.8188
Beta = 0.719
Revenue TTM = 1.83b USD
EBIT TTM = 362.0m USD
EBITDA TTM = 444.4m USD
Long Term Debt = 553.2m USD (from longTermDebt, last quarter)
Short Term Debt = 34.4m USD (from shortTermDebt, last quarter)
Debt = 776.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 509.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.91b USD (3.41b + Debt 776.0m - CCE 279.7m)
Interest Coverage Ratio = 7.75 (Ebit TTM 362.0m / Interest Expense TTM 46.7m)
FCF Yield = 8.28% (FCF TTM 323.2m / Enterprise Value 3.91b)
FCF Margin = 17.63% (FCF TTM 323.2m / Revenue TTM 1.83b)
Net Margin = 13.74% (Net Income TTM 252.0m / Revenue TTM 1.83b)
Gross Margin = 58.51% ((Revenue TTM 1.83b - Cost of Revenue TTM 760.5m) / Revenue TTM)
Gross Margin QoQ = 59.18% (prev 59.45%)
Tobins Q-Ratio = 1.36 (Enterprise Value 3.91b / Total Assets 2.87b)
Interest Expense / Debt = 1.43% (Interest Expense 11.1m / Debt 776.0m)
Taxrate = 20.57% (15.8m / 76.9m)
NOPAT = 287.5m (EBIT 362.0m * (1 - 20.57%))
Current Ratio = 0.98 (Total Current Assets 567.2m / Total Current Liabilities 576.6m)
Debt / Equity = 0.53 (Debt 776.0m / totalStockholderEquity, last quarter 1.46b)
Debt / EBITDA = 1.15 (Net Debt 509.8m / EBITDA 444.4m)
Debt / FCF = 1.58 (Net Debt 509.8m / FCF TTM 323.2m)
Total Stockholder Equity = 1.44b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.79% (Net Income 252.0m / Total Assets 2.87b)
RoE = 17.49% (Net Income TTM 252.0m / Total Stockholder Equity 1.44b)
RoCE = 18.16% (EBIT 362.0m / Capital Employed (Equity 1.44b + L.T.Debt 553.2m))
RoIC = 14.25% (NOPAT 287.5m / Invested Capital 2.02b)
WACC = 7.55% (E(3.41b)/V(4.18b) * Re(9.01%) + D(776.0m)/V(4.18b) * Rd(1.43%) * (1-Tc(0.21)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.68%
[DCF Debug] Terminal Value 78.36% ; FCFE base≈290.4m ; Y1≈358.2m ; Y5≈611.2m
Fair Price DCF = 239.0 (DCF Value 8.68b / Shares Outstanding 36.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 85.79 | EPS CAGR: 25.35% | SUE: 1.40 | # QB: 8
Revenue Correlation: 92.29 | Revenue CAGR: 6.03% | SUE: 2.57 | # QB: 8
EPS next Quarter (2026-03-31): EPS=2.05 | Chg30d=-0.045 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-06-30): EPS=7.81 | Chg30d=+0.027 | Revisions Net=+2 | Growth EPS=+17.1% | Growth Revenue=+7.6%
EPS next Year (2027-06-30): EPS=8.87 | Chg30d=+0.078 | Revisions Net=+2 | Growth EPS=+13.5% | Growth Revenue=+6.0%
Additional Sources for ATGE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle